Turning Point Brands outlines 2026 Modern Oral gross sales of $330M-$350M while targeting >70% chain store count growth (NYSE:TPB)

Turning Point Brands (TPB) projects 2026 sales of $330M-$350M for its Modern Oral division, aiming for over 70% growth in chain store count. The company is publicly traded on the NYSE.

Original reporting
Published Nov 9, 2026, 6:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 6:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Turning Point Brands outlines 2026 Modern Oral gross sales of $330M-$350M while targeting >70% chain store count growth (NYSE:TPB) — source image
Decision brief

The 30-second read

$TPBNeutralMed
01

Why it matters

The guidance provides a forward‑looking view of revenue and store expansion, which may shape analyst forecasts and investor sentiment.

02

Market read

Guidance is the primary new information for TPB, influencing its valuation and peer comparisons.

03

What to watch

Potential impact of regulatory changes on oral tobacco products is not addressed.

Relevance 7/10Novelty 7/10Timing: post‑earnings guidance release

Background

Turning Point Brands is a U.S. listed consumer products company focused on oral tobacco and nicotine products.

Company-level read

Ticker impact

$TPBNeutralMedium confidence
Context

Turning Point Brands disclosed 2026 Modern Oral gross sales guidance of $330M-$350M and >70% chain store count growth.

Expected impact

potential modest pressure if guidance is below market expectations, upside if seen as strong growth.

Evidence & confidence

The numbers are material for a small-cap consumer company, but no surprise element is indicated.

Market effects

Sets a benchmark for the modern oral tobacco segment and may influence peer valuations.

Primarily affects U.S. consumer discretionary investors.

Limited to niche tobacco market; low global spillover.

Counterpoint

If investors expect higher growth, the guidance could be viewed as a disappointment.

Key entities

  • Turning Point Brands, Inc.

    Issuer of the disclosed 2026 guidance.

Related articles

$TPBMedAI 8/10

Why Turning Point Brands Stock Got Socked Today

Turning Point Brands (NYSE:TPB) stock fell 11% after filing a mixed shelf registration with the SEC, indicating plans to raise capital. The company registered various securities, including common and preferred stock, for potential sale. Proceeds will be used for general corporate purposes. Shelf registrations often concern investors due to potential dilution or increased debt.

$TPBMed

Turning Point Brands Inc (TPB) (Q3 2026) Earnings Call Highlights: Modern Oral Sales Double

Turning Point Brands Inc (TPB) reported Q3 2026 earnings, with adjusted EBITDA declining 41% YoY to $18M due to increased investments. Zig-Zag segment sales fell 15% YoY to $37M, while Stoker's gross margin decreased 416 bps. Modern Oral net revenue guidance for Q4 suggests potential sequential decline or slight increase. CEO David Glazek highlighted strong consumer adoption and positive retail distribution pipeline.

$TPBMed

What Turning Point Brands (TPB) Said on Its Q3 Earnings Call

Turning Point Brands (TPB) reported Q3 gross profit up 21% to $85M, with gross margin at 56%. Stoker's segment sales rose 52%, while Zig-Zag fell 15%. The company reaffirmed its full-year outlook and expects U.S. manufacturing to begin in 2027. TPB ended the quarter with $251M in cash and repurchased $10M of stock.

$TPBMed

Turning Point (TPB) Q3 2026 Earnings Call Transcript

Turning Point (TPB) reported Q3 2026 earnings, highlighting progress in consumer traction, distribution expansion, and infrastructure building. Net sales rose 27% YoY to $151M, driven by Modern Oral. Gross profit increased 21% to $85M, while adjusted EBITDA fell 41% YoY to $18M due to higher sales and marketing investments. Stoker's segment saw 52% YoY sales growth, with Modern Oral nicotine pouch sales up 103% YoY to $74M.

$TPBMedAI 8/10

Turning Point Brands Q3 2026 slides: Modern Oral surges, margins dip

Turning Point Brands (TPB) reported Q3 2026 revenue of $151.1M (+27% YoY) but adjusted EBITDA fell 41% to $18.4M due to investments in its Modern Oral nicotine pouch business. Modern Oral revenue surged 102.9% YoY to $74.4M, now 49% of total sales. Shares fell 7.32% post-earnings, trading at $64.01. The company reaffirmed FY 2026 guidance, projecting Modern Oral net sales of $260-270M and adjusted EBITDA of $70-80M.

$TPBMed

Turning Point Brands Announces Third Quarter 2026 Results

Turning Point Brands, Inc. (TPB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Turning Point Brands Announces Third Quarter 2026 Results ● Q3 2026 Modern Oral Gross Sales increased 114.2% to $93.9 million and Net Sales increased 102.9% to $74.4 million, accounting for 49.2% of total company Net Sales ● Reaffirming FY 2026 Modern Oral Gross and